Lupin inks pact to commercialize Novel Antidepressant DeslaFlex in Canada

16 Feb 2026 Evaluate

Lupin has signed a licence and supply agreement with Spektus Pharma (Spektus), a specialty pharmaceutical company to commercialize the novel antidepressant DeslaFlex in Canada.  DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform.

This strategic partnership combines Lupin’s strong commercial footprint in Canada and Spektus’s capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex and establish a robust platform for future launches. The collaboration further strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2247.80 27.30 (1.23%)
17-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.40
Dr. Reddys Lab 1285.00
Cipla 1343.35
Zydus Lifesciences 906.75
Lupin 2247.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×